+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Subcutaneous Immunoglobulin Market by Indication (Primary Immunodeficiencies, Secondary Immunodeficiencies), End-User (Homecare Settings, Hospitals & Clinics) - Forecast 2024-2030

  • PDF Icon

    Report

  • 187 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5889355
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Subcutaneous Immunoglobulin Market size was estimated at USD 9.47 billion in 2023, USD 10.46 billion in 2024, and is expected to grow at a CAGR of 10.82% to reach USD 19.46 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Subcutaneous Immunoglobulin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Subcutaneous Immunoglobulin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Subcutaneous Immunoglobulin Market, highlighting leading vendors and their innovative profiles. These include Biotest AG by Grifols S.A., CSL Behring, Kedrion Biopharma Inc., Octapharma AG, Takeda Pharmaceutical Company Limited, and The Bio Products Laboratory.

Market Segmentation & Coverage

This research report categorizes the Subcutaneous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Primary Immunodeficiencies
    • Secondary Immunodeficiencies
  • End-User
    • Homecare Settings
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Subcutaneous Immunoglobulin Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Subcutaneous Immunoglobulin Market?
  3. What are the technology trends and regulatory frameworks in the Subcutaneous Immunoglobulin Market?
  4. What is the market share of the leading vendors in the Subcutaneous Immunoglobulin Market?
  5. Which modes and strategic moves are suitable for entering the Subcutaneous Immunoglobulin Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Subcutaneous Immunoglobulin Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the prevalence of autoimmune disorders globally
5.1.1.2. Increasing usage of subcutaneous immunoglobulin in off-label indications
5.1.1.3. Growing investments in R&D programs by biotechnology and pharmaceutical companies
5.1.2. Restraints
5.1.2.1. Huge cost associated with subcutaneous immunoglobulin treatment
5.1.3. Opportunities
5.1.3.1. Rising government funding and increasing awareness about the usage of subcutaneous immunoglobulin treatment
5.1.3.2. Innovations in the administration of subcutaneous immunoglobulin
5.1.4. Challenges
5.1.4.1. Stringent government regulations and high risk of the side effects of the treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Subcutaneous Immunoglobulin Market, by Indication
6.1. Introduction
6.2. Primary Immunodeficiencies
6.3. Secondary Immunodeficiencies
7. Subcutaneous Immunoglobulin Market, by End-User
7.1. Introduction
7.2. Homecare Settings
7.3. Hospitals & Clinics
8. Americas Subcutaneous Immunoglobulin Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Subcutaneous Immunoglobulin Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Subcutaneous Immunoglobulin Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Biotest AG by Grifols S.A.
12.1.2. CSL Behring
12.1.3. Kedrion Biopharma Inc.
12.1.4. Octapharma AG
12.1.5. Takeda Pharmaceutical Company Limited
12.1.6. The Bio Products Laboratory
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 2. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2022 VS 2030
FIGURE 3. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. SUBCUTANEOUS IMMUNOGLOBULIN MARKET DYNAMICS
FIGURE 7. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 8. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 10. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 12. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 14. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 20. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 6. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 9. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 12. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 14. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 15. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 16. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 17. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 18. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 19. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 21. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 25. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 98. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2022
TABLE 99. SUBCUTANEOUS IMMUNOGLOBULIN MARKET LICENSE & PRICING

Companies Mentioned

  • Biotest AG by Grifols S.A.
  • CSL Behring
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • The Bio Products Laboratory

Methodology

Loading
LOADING...

Table Information